Morning Market Losers
March 26, 2014 at 09:53 AM EDT
Exelixis (NASDAQ: EXEL) fell 36.03% to $4.12 after the company issued an update on ongoing COMET-1 phase 3 pivotal trial in men with ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.